AML Hub Podcast Advertising - Audience, Sponsors & Contact

Overview

The AML Hub podcast offers highly specialized medical education for healthcare professionals, researchers, and clinicians focused on Acute Myeloid Leukemia (AML). Each episode features leading experts discussing the latest advancements in AML classification, diagnosis, treatment, and management. The podcast delves into current and emerging therapies, analyzes clinical trial data, and explores the practical application of new treatments for specific genetic mutations like IDH1, NPM1, and KMT2A. With a professional and academic tone, it serves as a crucial resource for staying informed on cutting-edge research, bridging the gap between scientific discovery and clinical practice, and enhancing knowledge in this complex hematologic malignancy.

Show Impressions

Estimates only, not verified by show

Est. Total Impressions

336

Av. Youtube Views

336

Instagram

116

YouTubers Subscribers

929

Unlock show and brand data, including top ads, overall spend, and the ability to listen to ads.

Direct Response

Brands with CTAs

BAD

0%

Host Read %

% of host read ads

BAD

29%

Unlock show and brand data, including top ads, overall spend, and the ability to listen to ads.

The Bottom Line

This show has an estimated 336 audience size, runs 29% host read ads and promotes 0% of ads for direct response advertisers.

Creator Influence

Kim Sainty

The AML Hub operates as an open-access medical education platform managed by Scientific Education Support Ltd. The resource provides healthcare professionals with balanced updates on the diagnosis and management of acute myeloid leukemia. Utilizing named formats such as the Clinical Research Round-up and the 'How I Treat' expert series, the platform distills complex trial data into actionable insights for the oncology community. Content delivery focuses on high-level scientific communication, featuring contributions from a global Steering Committee comprising leading hematology trialists. A recent win includes the ASH 2025 Congress coverage, which provided rapid-response video analysis of menin inhibitor combination strategies and phase Ib/II data for CD123+ AML treatments. By collaborating with professional societies like the European Hematology Association (EHA), the hub ensures the dissemination of European LeukemiaNet guidelines and therapy approvals to international treatment teams and researchers seeking evidence-based articles and expert opinions.

Age: 10 years
Nationality: British
Education: MD/PhD, Multiple Medical Institutions

Age: 10 years
Nationality: British
Education: MD/PhD, Multiple Medical Institutions

Unlock show and brand data, including top ads, overall spend, and the ability to listen to ads.

Recent Campaigns

	Advertisers	Week5/11	Week5/18	Week6/29
Daiichi Sankyo Inc.daiichisankyo.com	Daiichi Sankyo Inc.		2	1	Test in progress 8%
In the Heart of Carejnj.com	In the Heart of Care		1		Test run 0%
Kuro Oncologykuraoncology.com	Kuro Oncology	1			Test run 0%

Demographics

Location

Fans by country:

United States 88%

Canada 4%

United Kingdom 3%

Germany 3%

Australia 2%

Age Distribution

18-24

12.0%

25-34

28.0%

35-44

26.0%

45-54

18.0%

55-64

11.0%

65-99

5.0%

Income Brackets

$10k-20k

4.0%

$20k-30k

7.0%

$30k-40k

9.0%

$40k-50k

11.0%

$50k-60k

13.0%

$60k-70k

12.0%

$70k-80k

11.0%

$80k-90k

10.0%

$90k-100k

9.0%

$100k-150k

8.0%

$150k-200k

4.0%

$200k-1000k

2.0%

Gender

Male · 58.0%

Male58.0%
Female37.0%
Other5.0%

Education

Bachelor's

42.0%

Graduate

28.0%

High School

18.0%

Post Graduate

12.0%

Occupation

Professional

32.0%

Student

18.0%

Management

14.0%

Other

13.0%

Sales

12.0%

Technical

11.0%

Family Status

Single · 42.0%

Single42.0%
Married35.0%
Parents23.0%

Ethnicity

White

68.0%

Hispanic

14.0%

Black

11.0%

Asian

7.0%

Engagement Style

Active listener

46.0%

Background listener

32.0%

Binge listener

22.0%

Language

English

94.0%

Spanish

4.0%

French

2.0%

Religion

Christianity · 52.0%

Christianity52.0%
Non-Religious48.0%

Brand Safety

Overall content risk rate

Low risk

35.0%

Risk breakdown

Share of content flagged by category

Explicit Language28.0%
Political Content5.0%
Violence2.0%

Unlock show and brand data, including top ads, overall spend, and the ability to listen to ads.

Top Advertisers

Top Spenders	Est. Spent	Change	Host Read %	DR %	# of ads	Frequency	Top Shows
Daiichi Sankyo Inc. pharmaceuticals	$15	+100.0%	50%	0%	4.0ad units	Core Performer	+1
In the Heart of Care hospital & health care	$7	0.0%	0%	0%	2.0ad units	Test run	+1
Kuro Oncology	$3	0.0%	0%	0%	1.0ad units	Test run

Ads and Episodes

Treatment decisions in AML: Personalizing care with FLT3 inhibitor therapy

0:00 / 0:11

Brand Awareness

T

#1

Run on 1x episode

‌
‌
‌
‌

Unlock show and brand data, including top ads, overall spend, and the ability to listen to ads.

Recent Episodes

‌
‌
‌